No going back

No going back

Understanding the first cell fate decision in development

The earliest cell fate decision in development creates two distinct cell populations: trophoblast cells that go on to form the yolk sac and placenta, and embryonic cells that develop into the embryo itself and all subsequent cell types of the body. This very first lineage decision can be most effectively studied by using mouse stem cells representing these first two lineages, i.e. trophoblast (TS) and embryonic (ES) stem cells, respectively.
Over the past years we have learnt, in work that resulted in a Noble Prize for Shinya Yamanaka and John Gurdon, that cells of the adult body can be reprogrammed back to a developmentally much earlier, ES-like state. However, the conditions to overcome the very first cell fate decision, which would enable an embryo-derived cell to functionally contribute to the placenta, had not been tested in great depth. Work by Babraham Institute researchers just published in the journal Nature Communications now shows that this earliest, most fundamental differentiation event in development between the embryonic and trophoblastic lineages is much more robust than previously appreciated.
Commitment to different cell lineages is in part due to cells acquiring distinct patterns of epigenetic marks that control which genes in the genome are expressed and which ones are stably repressed. Epigenetics refers to chemical modifications to DNA that do not affect its sequence but which affect gene expression. These marks fix the identity of the cell and prevent it from reverting into other cell types.
Although in the developing embryo, the decision between embryonic and placental trophoblast cells is irreversible, ES cells can be manipulated in experimental conditions to partially switch identities. The researchers, led by Dr Myriam Hemberger, assessed the effectiveness of a range of strategies to reprogramme ES cells to become TS-like cells, including expressing key transcription factors (proteins that control the expression of genes) that promote TS cell identity in ES cells, and switching on critical signalling pathways.
They demonstrated that the identity of ES cells cannot be fully overwritten and identified a vital set of genes that are epigenetically regulated and resistant to reprogramming, thereby preventing cross-over between the embryonic and trophoblast cell lineages. The epigenetic regulation of these core genes is central in perpetuating the first cell fate decision in early embryo development and determining the developmental potential of the two different stem cell populations.
Dr Hemberger, Group leader at the Babraham Institute, said: “This research contributes to our understanding of how cell identity is maintained in the first two cell lineages and why ES cells are resilient to reprogramming into placental trophoblast cells. These tight lineage-reinforcing barriers may serve to protect the embryo from accidentally forming trophoblast derivatives within its own tissues that would be fatal for its development.
“This work will help us drive forward the establishment of relevant models of early human trophoblast that will be instrumental for advancing our understanding of the most common pregnancy complications such as pre-eclampsia and fetal growth restriction.”

Image description:

ES cells reprogrammed for 5-6 weeks towards a TS-like fate by induction of  the transcription factor Cdx2 and Raf signalling, stained for the TS cell transcription factors Cdx2 (green) and Elf5 (red). Nuclei are in blue. The co-expression of Cdx2 and Elf5 that is typical for true TS cells is unstable and frequently lost in these reprogrammed TS-like cells. Concomitant with that is a lack of true TS cell self-renewal potential.

Related content

For more on stem cell reprogramming see: Wiping the slate clean

Associated researchers (in author order):

Francesco Cambuli & Alexander Murray, PhD students and joint first authors (Hemberger Lab)
Wendy Dean, Senior research scientist
Dominika Dudzinska, PhD student (Hemberger Lab)
Felix Krueger, Bioinformatician
Simon Andrews, Head of Bioinformatics
Claire Senner, Postdoc researcher (Hemberger Lab)
Simon Cook, Group Leader, Signalling
Myriam Hemberger, Group Leader, Epigenetics

Louisa Wood, Communications Manager
The Babraham Institute
Babraham Research Campus
Cambridge CB22 3AT
United Kingdom
Notes to Editors:
About the Babraham Institute:
The Babraham Institute undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.
The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around £450 million in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, health and well-being and pharmaceutical sectors. BBSRC carries out its mission by funding internationally competitive research, providing training in the biosciences, fostering opportunities for knowledge transfer and innovation and promoting interaction with the public and other stakeholders on issues of scientific interest in universities, centres and institutes.